Litcius/Paper detail

New therapeutic targets to reduce inflammation-associated cardiovascular risk: the CCL2–CCR2 axis, LOX-1, and IRF5

Filippo Crea

2022European Heart Journal10 citationsDOIOpen Access PDF

Topics & Concepts

MedicineInflammationIRF5CCR2CCL2Innate immune systemImmunologyChemokineImmune systemInterferon regulatory factorsChemokine receptorAtherosclerosis and Cardiovascular DiseasesInflammatory mediators and NSAID effectsEicosanoids and Hypertension Pharmacology
New therapeutic targets to reduce inflammation-associated cardiovascular risk: the CCL2–CCR2 axis, LOX-1, and IRF5 | Litcius